Abstract | BACKGROUND: OBJECTIVE: METHODS:
Migraine patients and matched nonmigraine control subjects were identified from the General Practice Research Database. Computerized records were searched for triptan prescriptions, stroke, TIA, MI, IHD, death, arrhythmia, and confounding variables. Incidence rates were calculated and migraine groups compared with controls using a Cox model, adjusting for confounders. RESULTS: Of 63,575 migraine patients, 13,664 were prescribed a triptan. There was no association between triptan prescription and stroke (hazard ratio [HR] 1.13; 95% CI 0.78, 1.65), MI (HR 0.93; 95% CI 0.60, 1.43), or other outcomes studied. The larger group of migraine patients not prescribed a triptan had an increased risk of stroke (HR 1.51; 95% CI 1.26, 1.82) and IHD (HR 1.35; 95% CI 1.18, 1.54) and a decreased risk of all-cause mortality (HR 0.72; 95% CI 0.65, 0.80). CONCLUSIONS: In general practice, triptan treatment in migraine does not increase the risk of stroke, MI, cardiovascular death, IHD, or mortality. Triptans are prescribed to those less at risk of these events.
|
Authors | Gillian C Hall, Martin M Brown, Jingping Mo, Kenneth D MacRae |
Journal | Neurology
(Neurology)
Vol. 62
Issue 4
Pg. 563-8
(Feb 24 2004)
ISSN: 1526-632X [Electronic] United States |
PMID | 14981171
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Analgesics, Non-Narcotic
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Sumatriptan
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Analgesics, Non-Narcotic
(adverse effects)
- Cardiovascular Diseases
(chemically induced, epidemiology)
- Cause of Death
- Child
- Child, Preschool
- Cohort Studies
- Databases, Factual
- Female
- Humans
- Incidence
- Infant
- Male
- Middle Aged
- Migraine Disorders
(complications, drug therapy)
- Mortality
- Proportional Hazards Models
- Retrospective Studies
- Risk
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
(adverse effects)
- Stroke
(chemically induced, epidemiology)
- Sumatriptan
(adverse effects)
- United Kingdom
(epidemiology)
|